The BIST Forum 2026 brought together scientists and representatives from academic, economic and social institutions to discuss how frontier research can help build Europe’s industries of the future. The event also announced the recipients of the BIST To the Mothers of Science and Ignite programmes.
El Rey visita el Mobile Wold Congress donde comprueba los avances de la tecnología en la salud. Allí se reencuentra con Samuel Sánchez, que presenta sus nanorrobots.
Experts in nanomedicine met yesterday, 5 March, to discuss the latest advances in the study, diagnosis and treatment of rare diseases. Nano Rare Diseases Day was organised once again to … Read more
This fourth workshop aims to bring together representatives from medical hospitals, pharma and spin-off companies, patient associations, and research groups to create an interactive panel discussion on rare diseases from … Read more
In a significant advancement for lab-on-chip technology, IBEC researchers in the frame of the European project BLOC, have demonstrated the first integration of a benchtop nuclear magnetic resonance (NMR) spectrometer … Read more
En el stand de Mobile World Capital Barcelona, una experiencia desarrollada conjuntamente con Nanobots Therapeutics muestra el potencial de los nanobots terapéuticos como nueva herramienta para el tratamiento de enfermedades como el cáncer. La empresa es una derivada del Institut de Bioenginyeria de Catalunya y de ICREA, y representa un paso adelante en la transferencia de investigación hacia la práctica clínica.
Three research projects led by IBEC researchers Xavier Rovira-Clavé, David Esporrín Ubieto and Aránzazu Villasante have been selected by the Spanish Association Against Cancer for its 2025 Grant Programme. The grant presentation ceremony, held in Barcelona today, recognised the momentum behind these initiatives, which range from advanced cell therapy platforms to smart nanomotors and innovative paediatric tumour treatment strategies.
Ref: TSTR – RJ // Deadline: 05/03/2026 –
Ref: Phd-PG // Deadline: 08/03/2026
Ref: PR-PG // Deadline: 05/03/2026